Opendata, web and dolomites

OnDosis01

A first in category prescription regimen for ADHD combining stimulants with intelligent dosing and digital capabilities

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "OnDosis01" data sheet

The following table provides information about the project.

Coordinator
ONDOSIS AB 

Organization address
address: ASTRAZENECA BIOVENTUREHUB, PEPPARED
city: MOLNDAL
postcode: 431 50
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.ondosis.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ONDOSIS AB SE (MOLNDAL) coordinator 50˙000.00

Map

 Project objective

The goal of this project is to develop a therapy that allows for more effective management of attention-deficit hyperactivity disorder (ADHD). ADHD is a common, childhood onset, neurobehavioural disorder characterised by a combination of inattention, hyperactivity and impulsivity impairing multiple areas of life. Stimulants are the most widely used ADHD medications and are proven effective on ADHD symptoms, but classified as controlled substances they are associated with concerns about side effects and potential for abuse. In addition, they require careful dose titration at initiation and throughout the patients’ life.

OnDosis aims to address these challenges by developing a novel “combination product”, prescribed as an ADHD treatment regime, that combines a technological platform with stimulant active compounds. This integrated solution will simplify dose titration, enable ease of swallowing, offer adherence support and self-monitoring checks. Importantly, OnDosis’ solution is a personalised device with the potential to reduce risk for medication abuse through tamper resistance and tamper evident features.

The ultimate success of the project will depend on generation of clinical data which will support partnering and out-licensing. OnDosis plans to apply for SMEi Phase 2 grant to take the product through required clinical studies, and then go to market through a licensing agreement with a strong commercial partner. OnDosis has a strong network established with potential pharma partners and investors, and has already gained support from investors that offer strategic support to the company.

The burden of ADHD is increasing and the unmet need is growing. This encourages OnDosis in the endeavour of a needs-driven research to address this widespread challenge. Market research with several stakeholders in healthcare have convinced OnDosis of the potential to bring significant impact to patients with ADHD through this novel technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONDOSIS01" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONDOSIS01" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More